The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC).
 
Benjamin A. Krantz
Stock and Other Ownership Interests - Acadia Pharmaceuticals; Aurinia Pharmaceuticals; Cellectis; Dynavax Technologies; Exelixis; Fate Therapeutics; Genocea Biosciences; Intra-Cellular Therapies; Juno Therapeutics; Minerva Neurosciences; Neuralstem; Novavax; Ocular Therapeutix; Paradigm Shift Therapeutics
 
Dana Tsui
Consulting or Advisory Role - Inivata
Patents, Royalties, Other Intellectual Property - Inivata
 
Maeve Aine Lowery
Consulting or Advisory Role - Agios; Celgene
 
Marinela Capanu
No Relationships to Disclose
 
Kenneth H. Yu
Consulting or Advisory Role - celgene; Merck Serono; Merrimack
 
David Paul Kelsen
No Relationships to Disclose
 
Erika Gedvilaite
No Relationships to Disclose
 
Liguo Zhang
No Relationships to Disclose
 
S Duygu Selcuklu
No Relationships to Disclose
 
Daoqi You
No Relationships to Disclose
 
Jennifer S Golia Pernicka
No Relationships to Disclose
 
Richard K. G. Do
No Relationships to Disclose
 
Christine A Iacobuzio-Donahue
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Agios (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Blueprint Medicines (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); Delcath Systems (I); Eisai (I); Gilead Sciences; Halozyme (I); IntegraGen (I); Ipsen (I); Janssen; MedImmune; Merck (I); Merrimack; New B Innovation (I); Newlink Genetics; Onxeo (I); Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); VAXIMM; Vicus Therapeutics; Westhaven (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst)